Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Research analysts at Leerink Swann raised their FY2018 EPS estimates for Protagonist Therapeutics in a note issued to investors on Tuesday. Leerink Swann analyst J. Schwartz now forecasts that the company will post earnings of ($1.82) per share for the year, up from their prior forecast of ($3.38). Leerink Swann also issued estimates for Protagonist Therapeutics’ FY2019 earnings at ($2.88) EPS.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Monday, November 6th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.40. The company had revenue of $8.78 million for the quarter. COPYRIGHT VIOLATION NOTICE: This report was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.watchlistnews.com/protagonist-therapeutics-inc-forecasted-to-earn-fy2018-earnings-of-1-82-per-share-ptgx/1697760.html.

A number of other research analysts have also recently issued reports on PTGX. BMO Capital Markets lifted their price target on Protagonist Therapeutics from $40.00 to $43.00 and gave the company an “outperform” rating in a report on Tuesday, November 7th. Zacks Investment Research raised Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a report on Saturday. ValuEngine cut Protagonist Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 11th. Finally, BTIG Research began coverage on Protagonist Therapeutics in a report on Friday, July 21st. They issued a “buy” rating and a $36.00 price target for the company.

Protagonist Therapeutics (NASDAQ:PTGX) opened at $17.05 on Friday. Protagonist Therapeutics has a twelve month low of $8.00 and a twelve month high of $26.36.

A number of large investors have recently made changes to their positions in the business. Wells Fargo & Company MN raised its holdings in Protagonist Therapeutics by 60.8% during the 3rd quarter. Wells Fargo & Company MN now owns 9,565 shares of the company’s stock worth $169,000 after purchasing an additional 3,617 shares during the last quarter. First Manhattan Co. bought a new stake in Protagonist Therapeutics during the 3rd quarter worth about $293,000. California State Teachers Retirement System raised its holdings in Protagonist Therapeutics by 8.5% during the 2nd quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock worth $188,000 after purchasing an additional 1,300 shares during the last quarter. State Street Corp raised its holdings in Protagonist Therapeutics by 20.9% during the 2nd quarter. State Street Corp now owns 112,474 shares of the company’s stock worth $1,270,000 after purchasing an additional 19,411 shares during the last quarter. Finally, Senzar Asset Management LLC bought a new stake in Protagonist Therapeutics during the 2nd quarter worth about $3,094,000. 39.84% of the stock is owned by hedge funds and other institutional investors.

In related news, insider Richard S. Shames sold 2,017 shares of Protagonist Therapeutics stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $19.00, for a total value of $38,323.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Y. Liu sold 3,500 shares of the business’s stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $15.00, for a total value of $52,500.00. Following the sale, the insider now directly owns 5,500 shares of the company’s stock, valued at $82,500. The disclosure for this sale can be found here. Insiders sold 10,716 shares of company stock valued at $169,288 over the last ninety days.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Earnings History and Estimates for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.